Britain got a lift in its pursuit of stem cell research last month with the announcement of the country's first cloning of a stem cell line from human embryonic cells.
A team at King's College London made the announcement as the high cost of using cells from the handful of other cell lines established around the world since 1998 was increasingly hampering research.
Their achievement puts the UK among a handful of other countries at the forefront of the field. It heralds an era of much cheaper and readily available stem cells for researchers in the UK and Europe.
Cells should be available to researchers later this year when the King's College team have grown sufficient numbers to deposit some in the UK stem cell bank, run by the Medical Research Council.
Stephen Minger, a member of the group, said they used 58 embryos to generate three stem-cell populations, but two were lost at an early stage. But he said this was fewer embryos than was used by other groups and attributed the success to the use of donated embryos that had been screened for genetic disorders, rather than discarded embryos from in vitro fertilisation procedures which may not be of sufficient quality.
The first human embryonic stem cell lines were created in 1998. There are just nine lines available across the world, the majority from Singapore, and they are extremely expensive.
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How do they function in polarity?
The mechanism by which the complexes mediate polarity at the cell biological level is not understood. The PDZ proteins act as scaffolds, without clear effector activities. It is suspected that polarizing activity is mediated by effector partners, such as the kinase aPKC and its substrate Lgl, which may be involved in vesicle transport or cytoskeletal regulation. Other effector partners, particularly those that interface with basic cell biological machinery, remain to be identified. Epithelial cell
Might they be involved in human

